跳至主要内容
临床试验/NCT07582770
NCT07582770尚未招募不适用

Validation of Neuropsychological Tests for the Assessment of Cognitive Impairment in Breast Cancer Survivors

European Institute of Oncology1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2026年5月1日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
200
试验地点
1

研究概览

简要总结

This study is a monocentric, observational, cross-sectional study with a case-control design, aimed at evaluating the construct validity, discriminative ability, and diagnostic accuracy of a second-level neuropsychological test battery for the detection of cancer-related cognitive impairment in breast cancer survivors.

详细描述

Participants will undergo a comprehensive neuropsychological assessment including both paper-and-pencil tests to be validated and their corresponding comparator instruments, in order to evaluate sensitivity, specificity, and convergent validity across multiple cognitive domains.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Age between 18 and 65 years old
  • Patient with a previous documented diagnosis of non-metastatic breast cancer (only for breast cancer survivor gruop)
  • Patient has completed chemotherapy for at least 6 months and for a maximum of 36 months if planned (only for breast cancer survivor gruop)
  • Understanding of the Italian language and ability to give informed consent

排除标准

  • Presence of brain metastases or history of brain radiation therapy (only for breast cancer survivor gruop)
  • Patient with previous diagnosis of other malignant tumors in addition to breast cancer (only for breast cancer survivor gruop)
  • Patient with a previous diagnosis of malignant carcinomas (only for control gruop)
  • Patient with a history of brain damage with unresolved neurological consequences
  • Patient with previous or current serious neurological pathologies
  • Patient with severe psychiatric conditions
  • Patient with systemic pathologies that could interfere with cognitive abilities
  • Patient taking medications that have a strong cognitive impact and that have not been stabilized for at least 4 weeks prior to enrollment
  • Patient with visual or hearing impairments that are not properly corrected
  • Patient with any disability that might compromise the validity of cognitive tests

研究者

发起方
European Institute of Oncology
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验